Athenex, a biopharmaceutical company, agreed to acquire Kuur Therapeutics, developer of cell immunotherapies for the treatment of solid and hematological malignancies, from Schroder, a closed-ended investment company, for $185m. “Kuur’s innovative technology, combined with our TCR program, could propel us into a leadership position in cell therapy. This platform also has the potential to provide synergies with other assets in our pipeline,” Johnson Lau, Athenex CEO.